Chase Bank USA, N.A.

Chase Bank USA, N.A. ("Chase USA") was a national banking association and the credit-card-issuing bank of JPMorgan Chase & Co. (NYSE: JPM). Its registered office was in Wilmington, Delaware — the charter originated as Bank One, Delaware, N.A. and took the Chase Bank USA name after JPMorgan Chase's 2004 acquisition of Bank One. It was never separately traded; as a wholly owned subsidiary, standalone headcount and revenue were not separately disclosed. In December 2018 JPMorgan Chase filed an OCC merger application, and effective May 18, 2019, Chase USA merged into JPMorgan Chase Bank, N.A., which survived. The entity in the case data therefore no longer exists as a separate legal person.

Operations. As issuer bank, Chase USA originated and issued Visa and Mastercard consumer and small-business credit cards, including co-brand and partner programs, and held card receivables later transferred to Chase Card Funding and securitized through the Chase Issuance Trust. Its SEC Regulation AB filings also show it as a defendant in the merchant interchange antitrust MDL. This is an operating bank entity, not an NPE or shell licensor.

Litigation posture. Chase USA appears only as a defendant (0 plaintiff, 1 defendant), consistent with a large operating institution defending third-party patent claims rather than asserting its own portfolio. Its sole tracked suit was filed in the Southern District of New York — not an EDTX-style plaintiff-friendly venue — and concerned the bank's own use of commercially purchased security hardware.

Notable case. Intellectual Ventures II LLC v. JPMorgan Chase & Co., No. 1:13-cv-03777-AKH (S.D.N.Y., filed June 4, 2013). IV asserted five patents (’084, ’409, ’574, ’694, ’666) against JPMorgan Chase entities including Chase USA and Chase Paymentech, targeting IBM cryptographic coprocessors used in network security. In April 2015 the court granted partial summary judgment of patent-ineligibility on three patents; a fourth was withdrawn, leaving the ’666 patent. The court declined to stay pending CBM review, producing the Federal Circuit appeal reported at 781 F.3d 1372.